Quantcast
Last updated on April 18, 2014 at 17:16 EDT

BioElectronics Announces Study on Bone Regeneration Published in the Journal of Craniofacial Surgery

April 5, 2012

FREDERICK, Md., April. 5, 2012 /PRNewswire/ — BioElectronics Corporation. (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the publication of an article in the peer reviewed journal The Journal of Craniofacial Surgery – Differentiation of osteoprogenitor cells is induced by high-frequency pulsed electromagnetic fields. Teven CM, Greives M, Natale RB, Su Y, Luo Q, He BC, Shenaq D, He TC, Reid RR J Craniofac Surg. 2012 Mar;23(2):586-93). The study was an independent study from the University of Chicago Medical School, Department of Plastic Surgery.

Since the 1970′s pulsed electromagnetic field therapy (PEMF) has been used for the healing of non-union bone fractures. The natural extension has been its use to stimulate bone regeneration. Bone reconstruction and regeneration is important in craniofacial surgery, segmental defect due to tumor removal, augmentation of bone around a hip implant revision and reconstruction of bone in the jaw for dental purposes. A number of reports have shown results of achieving bone formation from terminally differentiated osteoblasts cells after exposure to low frequency (3 – 50Hz) PEMF. However, cofactors are often needed to get an adequate cellular differentiation and bone formation.

A study led by Russell R. Reid, MD, PhD, a leading researcher in craniofacial disorders at the University of Chicago Medical School utilized BioElectronics’ ActiPatch to transform two cell lines of pluripotent osteoprogenitor cells into bone. Osteoprogenitor cells are important targets for bone tissue engineering because of their large quantity in humans and their ease of isolation. The unique findings from this study were that successful bone formation was observed from the pluripotent osteoprogenitor cells, and without the need of cofactors. Effective bone formation without the need for cofactors is an important aspect of a successful bone regeneration therapy.

“It has been clear to us for a long time that our products stimulate cellular repair and growth. We have our own limited bone growth study, so we are therefore very excited by this excellent research, which may lead to an effective method for bone regeneration and aid in reconstructive surgery,” Commented Ian Rawe, Ph.D., BioElectronics Director of Research. “We are also confident that this peer reviewed publication of this clinical study benefits BioElectronics in gaining greater recognition and acceptance for our innovative products in the medical community.”

About BioElectronics Corporation
BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay(TM) Menstrual Cycle Pain Therapy, and RecoveryRx(TM) for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com/.

Contact: E & E Communications
Paul Knopick
(949) 707-5365

SOURCE BioElectronics Corporation


Source: PR Newswire